Immune-mediated mechanisms influencing the efficacy of anticancer therapies

Trends in Immunology

Volumn 36, Issue 4, 2015, Pages 198-216

  Coffelt, Seth B ^a   de Visser, Karin E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adaptive immune cells; Anticancer therapy; Cancer; Inflammation; Mouse model

Indexed keywords

CYTOTOXIC AGENT; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE CELL FUNCTION ASSAY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; METASTASIS; NONHUMAN; PHENOTYPE; REVIEW; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 84926506596     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.02.006     Document Type: Review

References (205)

1. Krumbhaar E.B., Krumbhaar H.D. The blood and bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases. J. Med. Res. 1919, 40:497-508.
2. Goodman L.S., et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc. 1946, 132:126-132.
3. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5:65-72.
4. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68:8643-8653.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
6. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
7. Ries C.H., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
8. Olive K.P., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
9. DuPage M., et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
10. Garbe A.I., et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res. 2006, 66:508-516.
11. Singh M., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
12. DuPage M., Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 2013, 25:192-199.
13. Dranoff G. Intensifying tumour immunity through combination therapy. Lancet Oncol. 2012, 13:440-442.
14. Singh M., et al. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012, 72:2695-2700.
15. De Palma M., Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 2012, 6:111-127.
16. Singh M., Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotechnol. 2012, 30:648-657.
17. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
18. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
19. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
20. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
21. Mantovani A., et al. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice. J. Natl. Cancer Inst. 1979, 63:61-66.
22. DeNardo D.G., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
23. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
24. Shree T., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
25. Houthuijzen J.M., et al. Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. Nat. Commun. 2014, 5:5275.
26. Lin E.Y., et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
27. Stanley E.R., et al. CSF-1 - a mononuclear phagocyte lineage-specific hemopoietic growth factor. J. Cell Biochem. 1983, 21:151-159.
28. Maroulakou I.G., et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:11236-11240.
29. Mitchem J.B., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
30. Paulus P., et al. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006, 66:4349-4356.
31. Germano G., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
32. Pahler J.C., et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
33. Swierczak A., et al. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol. Res. 2014, 2:765-776.
34. Pyonteck S.M., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
35. Zhu Y., et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-5069.
36. Rolny C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
37. De Palma M., et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
38. Kodumudi K.N., et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010, 16:4583-4594.
39. Dijkgraaf E.M., et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013, 73:2480-2492.
40. Nakasone E.S., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
41. Stockmann C., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
42. Guerriero J.L., et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J. Immunol. 2011, 186:3517-3526.
43. Ma Y., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
44. Acharyya S., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
45. + myeloid cells antagonize senescence in cancer. Nature 2014, 515:134-137.
46. Han Y., et al. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res. Treat. 2012, 131:483-490.
47. Di Maio M., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005, 6:669-677.
48. Bald T., et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014, 507:109-113.
49. Coffelt S.B., et al. IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015, (in press).
50. + granulocytes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21248-21255.
51. Youn J.I., et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
52. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
53. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
54. Vincent J., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
55. Alizadeh D., et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014, 74:104-118.
56. Bruchard M., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
57. Kanterman J., et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014, 74:6022-6035.
58. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
59. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
60. Casares N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202:1691-1701.
61. Gabrilovich D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
62. Broz M.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
63. Engelhardt J.J., et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012, 21:402-417.
64. de Visser K.E., et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
65. Andreu P., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
66. Schioppa T., et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10662-10667.
67. Affara N.I., et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014, 25:809-821.
68. Ma Y., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 208:491-503.
69. Guy C.T., et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10578-10582.
70. Muller A.J., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
71. Hannesdottir L., et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 2013, 43:2718-2729.
72. Savage P.A., et al. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013, 34:33-40.
73. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
74. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
75. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
76. Wu L., et al. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. J. Thorac. Oncol. 2011, 6:1578-1586.
77. Sahu R.P., et al. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 2014, 74:7069-7078.
78. Ganesan A.P., et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J. Immunol. 2013, 191:2009-2017.
79. Hanna N., Burton R.C. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J. Immunol. 1981, 127:1754-1758.
80. Sevko A., et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 2013, 190:2464-2471.
81. Mattarollo S.R., et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011, 71:4809-4820.
82. Sistigu A., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
83. Derksen P.W., et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449.
84. Muller W.J., et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
85. Ciampricotti M., et al. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346.
86. Begg A.C., et al. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11:239-253.
87. Liauw S.L., et al. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci. Transl. Med. 2013, 5:173sr2.
88. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
89. Ahn G.O., et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8363-8368.
90. Kioi M., et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120:694-705.
91. Xu J., et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013, 73:2782-2794.
92. Li F., et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell 2007, 26:63-74.
93. Kozin S.V., et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010, 70:5679-5685.
94. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
95. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
96. + T cells via dendritic cell activation. J. Immunol. 2012, 189:558-566.
97. Deng L., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014, 124:687-695.
98. Burnette B.C., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
99. Deng L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
100. + T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
101. Takeshima T., et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010, 70:2697-2706.
102. Bos P.D., et al. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 2013, 210:2435-2466.
103. Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
104. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
105. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
106. Smith M.P., et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov. 2014, 4:1214-1229.
107. Sommer G., et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6706-6711.
108. Cavnar M.J., et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J. Exp. Med. 2013, 210:2873-2886.
109. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
110. Park S., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
111. Grugan K.D., et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J. Immunol. 2012, 189:5457-5466.
112. Chao M.P., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142:699-713.
113. Minard-Colin V., et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008, 112:1205-1213.
114. Albanesi M., et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013, 122:3160-3164.
115. Simpson T.R., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
116. Taskinen M., et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 2007, 13:5784-5789.
117. Pander J., et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 2011, 17:5668-5673.
118. Toso A., et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 2014, 9:75-89.
119. Nefedova Y., et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005, 65:9525-9535.
120. Anders K., et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011, 20:755-767.
121. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
122. Wilmott J.S., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012, 18:1386-1394.
123. Ferrari de Andrade L., et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014, 74:7298-7308.
124. Knight D.A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 2013, 123:1371-1381.
125. Cooper Z.A., et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2014, 2:643-654.
126. Ho P.C., et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res. 2014, 74:3205-3217.
127. Dankort D., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41:544-552.
128. Borg C., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 2004, 114:379-388.
129. Yang Y., et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012, 120:4533-4543.
130. Balachandran V.P., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 2011, 17:1094-1100.
131. Powell J.D., et al. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 2012, 30:39-68.
132. Pollizzi K.N., Powell J.D. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 2015, 36:13-20.
133. Jiang Q., et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 2011, 71:4074-4084.
134. + T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res. 2014, 74:2217-2228.
135. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
136. Lin E.Y., et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66:11238-11246.
137. De Palma M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9:789-795.
138. Welford A.F., et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011, 121:1969-1973.
139. Gabrusiewicz K., et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 2014, 5:2208-2220.
140. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
141. Zhang W., et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16:3420-3430.
142. Fischer C., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-4675.
143. Priceman S.J., et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
144. Srivastava K., et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 2014, 26:880-895.
145. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
146. + myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
147. Chung A.S., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
148. Shojaei F., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-8231.
149. Shojaei F., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6742-6747.
150. Finke J.H., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 2008, 14:6674-6682.
151. Terme M., et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013, 73:539-549.
152. Ko J.S., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15:2148-2157.
153. Manning E.A., et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 2007, 13:3951-3959.
154. Dirkx A.E., et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006, 20:621-630.
155. Huang Y., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:17561-17566.
156. Sandhu S.K., et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 2013, 71:1041-1050.
157. Pienta K.J., et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest. New Drugs 2013, 31:760-768.
158. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
159. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
160. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
161. Powles T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
162. Herbst R.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
163. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
164. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
165. Snyder A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
166. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
167. Suzuki E., et al. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol. Ther. 2007, 6:880-885.
168. Shevchenko I., et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer 2013, 133:98-107.
169. Mokyr M.B., et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998, 58:5301-5304.
170. Lesterhuis W.J., et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE 2013, 8:e61895.
171. Walter S., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18:1254-1261.
172. Le D.T., Jaffee E.M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012, 72:3439-3444.
173. Wu L., et al. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol. Cancer Ther. 2012, 11:1809-1819.
174. Verbrugge I., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012, 72:3163-3174.
175. Demaria S., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005, 11:728-734.
176. Reits E.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 2006, 203:1259-1271.
177. Matsumura S., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
178. Ramakrishnan R., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120:1111-1124.
179. Zhang B., et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 2007, 204:49-55.
180. Liu C., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013, 19:393-403.
181. Koya R.C., et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012, 72:3928-3937.
182. Shrimali R.K., et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70:6171-6180.
183. Ugel S., et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012, 2:628-639.
184. +/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24:589-602.
185. Landsberg J., et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012, 490:412-416.
186. Highfill S.L., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 2014, 6:237ra67.
187. Fridlender Z.G., et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010, 70:109-118.
188. Devaud C., et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol. Ther. 2014, 22:18-27.
189. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477:526-528.
190. Guerin E., et al. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013, 73:2743-2748.
191. Munoz R., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006, 66:3386-3391.
192. Francia G., et al. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
193. Guy C.T., et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. 1992, 12:954-961.
194. Hagerling C., et al. Balancing the innate immune system in tumor development. Trends Cell Biol. 2014, Published online November 28, 2014, http://dx.doi.org/10.1016/j.tcb.2014.11.001.
195. Azab B., et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann. Surg. Oncol. 2012, 19:217-224.
196. Noh H., et al. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J. Breast Cancer 2013, 16:55-59.
197. Kitamura T., et al. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015, 15:73-86.
198. Diaz-Montero C.M., et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
199. Porembka M.R., et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 2012, 61:1373-1385.
200. Wang L., et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J. Immunol. 2013, 190:794-804.
201. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37.
202. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
203. Ojalvo L.S., et al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 2009, 174:1048-1064.
204. Pucci F., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
205. Xue J., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.